- There is no application.
Sort By :
Prolaris is a genomic test developed to aid healthcare professionals in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA.
The Myriad myRisk® Hereditary Cancer test is a 28-gene panel that identifies an elevated risk for eight hereditary cancers
EndoPredict’s accurate low-risk assessment can help patients consider safely forgoing chemotherapy
BRACAnalysis ® is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. BRCAmutations are responsible for the majority of hereditary breast and ovarian cancers. People with a mutation in either the BRCA1 or BRCA2 gene have risks of up to 87 percent for developing breast cancer and 39-63 percent for developing ovarian cancer by age 70. Mutation carriers previously diagnosed with cancer also have a significantly increased risk of developing a second primary cancer. In fact, patients with these types of mutations have an up to 64 percent chance of developing a second breast cancer by age 70.
Get In Touch
Send your request and we will get in touch with you as soon as possible.